Document is current
Any future updates will be listed below
-
Authors
Schick, Alex https://orcid.org/0000-0003-3015-9138
Hardy, Sara
Strawderman, Myla https://orcid.org/0000-0002-6016-968X
Zheng, Dandan
Cummings, Michael
Milano, Michael T.
Magnuson, Allison
Behr, Jacqueline
Sammons, Sarah https://orcid.org/0000-0003-2589-9422
Usuki, Kenneth
Mohile, Nimish
O’Regan, Ruth
Anders, Carey K. https://orcid.org/0000-0001-9165-4074
Hicks, David
Dhakal, Ajay https://orcid.org/0000-0002-5140-158X
- License Information
-
More Information
Article History
Received: 29 February 2024
Accepted: 10 July 2024
First Online: 2 August 2024
Competing interests
: M.C. receives funding from Varian (Siemens) for technology unrelated to the treatment of brain lesions. M.T.M. receives royalties from Wolters Kluwer/UpToDate. R.O’R. receives research funding from Puma Biotechnology and is an advisor for Pfizer. C.A. receives research funding from Puma Biotechnology, Lilly, Merck, Seattle Genetics, Nektar, Tesaro, G1-Therapeutics, ZION, Novartis, Pfizer, Astra Zeneca, Elucida, Caris, and Incyclix, honoraria from Genentech, Eisai, IPSEN, Seattle Genetics, Astra Zeneca, Novartis, Immunomedics, Elucida, Athenex, and Roche, and receives royalties from UpToDate and Jones and Bartlett. A.D. receives research funding from Celcuity and Puma Biotechnology and honoraria from OncLive/MJH Life Sciences, Gilead Sciences, AstraZeneca, and WebMD/Medscape. The remaining authors declare no conflict of interest.
